Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA User Fee Work Continues Following House Passage

This article was originally published in The Pink Sheet Daily

Executive Summary

Bill moves to conference committee with House passage under suspension of the rules, but negotiators will have to reconcile pay-fors and track and trace differences.


Related Content

PDUFA Cost Offset In House Focuses On FDA Petition Review, Not REMS
On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts